Actively Recruiting
Assessment of Gixam Device Accuracy in Detecting Advanced and Non-advanced Colorectal Neoplasia Among Adults with Negative FIT Results
Led by Jubaan Ltd. · Updated on 2026-10-20
1436
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of the Gixam device for detecting pre-cancer or cancer in the colon and rectum in adults aged 45 to 84 who are at average risk for colorectal cancer and have had a negative Fecal Immunochemical Test FIT result. The study aims to determine if the Gixam device can identify colorectal neoplasia missed by the FIT test by comparing its results to those from a standard screening colonoscopy. Participants will undergo three main procedures the Gixam test, a FIT sample collected at home and sent to a lab, and a standard screening colonoscopy. All enrolled participants will receive these interventions, with the colonoscopy serving as the reference standard to assess the accuracy of the Gixam device. The study focuses on screening and does not include treatment interventions. During the study, participants will complete the Gixam test and FIT, followed by the colonoscopy. Researchers will monitor safety from enrollment up to 30 days after, and efficacy outcomes will be assessed through study completion, averaging 30 days. The study involves evaluating test results, collecting safety data, and comparing findings to help determine if the Gixam device is a useful screening tool for colorectal cancer.
CONDITIONS
Brief Title
Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here